<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The present study has been designed to investigate the potential of peroxisome proliferator-activated receptor-gamma ([PPAR]-Î³) <z:chebi fb="4" ids="48705">agonists</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> in <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>-induced vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> of rats </plain></SENT>
<SENT sid="1" pm="."><plain>l-methionine was administered for 8 weeks to induce <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e> and associated vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> were administered to l-methionine-treated rats for 4 weeks (starting from 5th to 8th weeks of methionine treatment) </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="53289,53290,53292">Donepezil</z:chebi> served as a positive control in this study </plain></SENT>
<SENT sid="4" pm="."><plain>On 52nd day onward, the animals were exposed to <z:mp ids='MP_0001465'>Morris water maze</z:mp> (MWM) for testing learning and memory abilities </plain></SENT>
<SENT sid="5" pm="."><plain>Vascular endothelial function, serum <z:chebi fb="95" ids="16301">nitrite</z:chebi>/nitrate levels, brain <z:chebi fb="0" ids="33202">thiobarbituric acid</z:chebi> reactive species (TBARS), brain reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH) levels, and brain acetylcholinesterase (AChE) activity were also measured </plain></SENT>
<SENT sid="6" pm="."><plain>l-methionine-treated animals have shown impairment of learning, memory, endothelial function, decrease in serum <z:chebi fb="95" ids="16301">nitrite</z:chebi>/nitrate levels, and brain GSH levels along with increase in brain TBARS levels and AChE activity </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi>, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, and <z:chebi fb="0" ids="53289,53290,53292">donepezil</z:chebi> significantly improved <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>-induced impairment of learning, memory, <z:e sem="disease" ids="C0856169" disease_type="Disease or Syndrome" abbrv="">endothelial dysfunction</z:e>, and changes in various biochemical parameters </plain></SENT>
<SENT sid="8" pm="."><plain>It is concluded that <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> may be considered as potential pharmacological agents for the management of <z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">hyperhomocysteinemia</z:e>-induced vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>